(Q38977579)
Statements
A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis (English)
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference